


04-05-04



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/681,788
Applicant: ZAGHOUBANI et al.
Filed: October 8, 2003
Art Unit: 1614
Examiner: unknown
Title: SUSTAINED TREATMENT OF
OF TYPE 1 DIABETES AFTER
EXPRESSION OF PREDISPOSITION
MARKERS
Docket No.: 03194161
Customer No.: 26565

CERTIFICATE OF MAILING BY
"EXPRESS MAIL"
"Express Mail" mailing label number
EL 300806625 US
Date of Deposit: April 2, 2004
I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail Post Office to Addressee" under 37
CFR 1.10 on the date indicated above and is
addressed to COMMISSIONER FOR PATENTS,
P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

typed or printed name of person mailing paper or
fee: Tim Hubalik


Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Dear Sir:

Enclosed herewith are the following for the above-captioned application:

1. Information Disclosure Statement;
2. Form PTO/SB/08B citing 4 references;
3. Copy of International Search Report;
4. Complete copies of 4 cited references; and
5. Return receipt postcard.

The Commissioner is hereby authorized to charge any additional filing fees required under Rule 1.17 concerning this transaction, or to credit any overpayment to Deposit Account 13-0019.

Respectfully submitted,



David B. Fournier
Reg. No. 51696

Date: April 2, 2004

MAYER, BROWN, ROWE & MAW LLP
P.O. Box 2828
Chicago, Illinois 60690-2828
Telephone: (312) 701-8034
Facsimile: (312) 706-9000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/681,788
Applicant: ZAGHOUBANI et al.
Filed: October 8, 2003
Art Unit: 1614
Examiner: unknown
Title: SUSTAINED TREATMENT OF TYPE 1
DIABETES AFTER EXPRESSION OF
PREDISPOSITION MARKERS
Docket No.: 03194161
Customer No.: 26565

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO/SB/08B form. The references submitted in this Information Disclosure Statement were cited in the International Search Report of a corresponding patent application. This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits. Therefore, Applicant believes no fee is due in connection with this filing.

Applicant respectfully requests that the Examiner consider the listed documents and evidence that consideration of relevant portions thereof by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each of all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is hereby authorized to charge any additional filing fees required under Rule 1.17 concerning this transaction, or to credit any overpayment to Deposit Account 13-0019.


Respectfully submitted,



David B. Fournier
Reg. No. 51696

Date: April 2, 2004

MAYER, BROWN, ROWE & MAW LLP
P.O. Box 2828
Chicago, Illinois 60690-2828
Telephone: (312) 701-8034
Facsimile: (312) 706-9000



PTO/SB/088
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/681,788
				Filing Date	October 8, 2003
				First Named Inventor	ZAGHOUBANI
				Art Unit	1614
				Examiner Name	unknown
Sheet	1	of	1	Attorney Docket Number	03194161

NON PATENT LITERATURE			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	BALASA, Balaji et al. "A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes" <i>The Journal of Immunology</i> , Vol 165 (2000) pp. 7330-7337.	
	2	LEGGE, K.L. et al. "Multi-modal antigen specific therapy for autoimmunity" <i>Int. Rev. Immunology</i> , Vol. 20 (October 2001) pp. 593-611.	
	3	LEGGE, K.L. et al. "Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T Cells and Ameliorates Experimental autoimmune encephalomyelitis" <i>J. Exp. Med.</i> , Vol. 191, No. 12 (June 19, 2000) pp. 2039-2051.	
	4	ZAMBIDIS, E.T. et al. "Epitope-specific tolerance induction with an engineered immunoglobulin" <i>Proc. Natl. Acad. Sci., USA</i> , Vol. 93 (May 1996) pp. 5019-5024.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.